अमूर्त

Anti-Mullerian hormone in young female with different phenotypes of polycystic ovary syndrome without additional risk factors for atherosclerosis in Bulgarian population

Nikoleta Parahuleva, Ekaterina Uchikova, Anna Mihaylova, Penka Petleshkova, Mariana S Parahuleva

Objective: Anti-Mullerian hormone (AMH) was highlighted as a valid marker of ovarian dysfunction in women with anovulatory polycystic ovarian syndrome (PCOS) and was linked with cardiovascular conditions. This study was designed to determine the circulating AMH levels in different phenotypes of PCOS without additional risk factors for atherosclerosis in Bulgarian cohort. Material and methods: A case-control single-center design was used. The levels of serum AMH were analyzed in non-pregnant, pre-menopausal women with PCOS, smoker or non-smoker, without other risk factors for atherosclerosis. Results: Significant elevated levels of AMH were observed in all phenotypes of PCOS. However, there are no significant differences between smokers and non-smokers. Serum levels of androgens in PCOS were increased nearly twice. In phenotype C there was a positive correlation between ??H and the androgens. The estradiol levels decreased significantly in the cases with polycystic ovaries. The comparison of the ROC curves shows statistical significant diagnostic efficacy of the variables to diagnose PCOS between AMH and testosteron (Z=4.586, P<0.001) as well as AMH and E2 (Z=6.450, P<0.001). Conclusion: Thus, AMH will be a more reliable diagnostic marker of PCOS than the well-known nonconstant clinical and hormonal parameters in non-pregnant, pre-menopausal women with different phenotypes of PCOS, smokers and non-smokers, without additional risk factors for atherosclerosis in Bulgarian cohort.